| CASE REPORT |
|
| Year : 2022 | Volume
: 9
| Issue : 2 | Page : 77-81 |
|
|
Marked Response to Chemoimmunotherapy in a Patient with Follicular Lymphoma of Huge Mesenteric Lymphadenopathy
Chia-Chen Li1, Shan-Chi Yu2, Sung-Hsin Kuo3
1 Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
2 Department of Pathology and Graduate Institute of Pathology, National Taiwan University College of Medicine; Department of Pathology, National Taiwan University Hospital; Graduate Institute of Microbiology, National Taiwan University College of Medicine, Taipei, Taiwan
3 Department of Oncology, National Taiwan University Hospital; Graduate Institute of Oncology; Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
Correspondence Address:
Dr. Sung-Hsin Kuo
Department of Oncology, National Taiwan University Hospital, No. 7, Zhongshan South Road, Taipei
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/JCRP.JCRP_35_21
|
|
|
Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin's lymphomas. We present the case of a 57-year-old woman who initially complained of abdominal fullness and unintentional weight loss. A computerized tomography scan disclosed a huge mesenteric mass and confluent lymphadenopathy in the paraaortic area, and the pathological diagnosis of a paraaortic lymph node biopsy showed histological Grade 1–2 FL. She received chemoimmunotherapy, including rituximab plus cyclophosphamide, vincristine, and prednisolone, for Ann Arbor Stage III FL disease accompanied by compression symptoms, and achieved a nearly complete remission after completing eight cycles of chemoimmunotherapy. She is currently receiving maintenance rituximab therapy.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
